DANCANN PHARMA A/S: Financial statements 2019
CVR: 39426005
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
DANCANN PHARMA A/S (CVR 39426005) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -421,797 and a net result of DKK -1,239,612. Equity in the 2019 report amounted to DKK -1,365,063. The company had 4 employees in the financial year.
- Gross Profit
- DKK -421,797
- Profit/Loss
- DKK -1,239,612
- Equity
- DKK -1,365,063
- Total Assets
- DKK 732,772
- Employees
- 4
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
On December 4, 2019, the company changed its name from DANCANN IVS to DANCANN PHARMA IVS.
DANCANN PHARMA A/S has published its interim report for the period March 20, 2018 – December 31, 2018.
About DANCANN PHARMA A/S
DANCANN PHARMA A/S is a Danish company of the type Aktieselskab based in Ansager, founded in 2018. The company is under bankruptcy. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named DANCANN PHARMA ApS and DANCANN PHARMA IVS. The company is owned by JEQ Capital AB. The company has 1 employee (2026). In 2024, the company reported a gross profit of DKK -148,000 and a net result of DKK -8,346,000 compared with DKK -62,260,000 the year before. Equity in the 2024 report amounted to DKK 14,620,000.